- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00948155
Measuring Smoking Behaviors While Using Varenicline
Assessment of Smoking Topography and Behaviors During Response to Varenicline
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Tobacco Use Research Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- self report minimum 10 daily cigarettes
- self report smoking every day past 5 years
- between the ages 21-65
- self report intention to try to quit smoking in the next 6 months
Exclusion Criteria:
- self reported use of any nicotine-containing products other than non-menthol cigarettes
- self reported history or current treatment of substance abuse (other than nicotine dependence)
- self reported alcohol use greater than 25 standard drinks per week;
- currently pregnant, planned pregnancy or lactating (females: negative urine pregnancy screen)
- self reported history or current diagnosis of any Axis 1 disorders except past depression
- self reported serious or unstable disease within past year
- self reported history of epilepsy or seizure disorder;
- self reported history or current diagnosis of COPD (chronic obstructive pulmonary disease), cardiovascular disease, heart attack, or uncontrolled hypertension
- self reported kidney function impairment
- any current or recent (30 day) use of: smoking cessation medications, anti-psychotics, anti-depressants, anti-anxiety, panic medications, stimulants or opiate-containing medications
- less than 5 years of daily smoking
- any medical condition or concomitant medication that could compromise participant safety or treatment
- provide a baseline carbon monoxide (CO) reading < 10 ppm
- self reported use of non filtered cigarettes
- inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Varenicline before placebo
Drug (Varenicline (Chantix)): Placebo Intervention to be administered is: participants will receive standard dosing regimen of Varenicline for 21 days total, followed by 14-day washout and 21 days of placebo. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21. |
Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
Autres noms:
|
|
Expérimental: Placebo then Varenicline
Placebo: Drug Varenicline (Chantix) Intervention to be administered is: participants will receive 21 days of placebo, followed by 14-day washout and standard dosing regimen of Varenicline for 21 days total. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21. Intervention 'Drug (Varenicline (Chantix)): Placebo' |
Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Smoking Topography: Total Puff Volume
Délai: Days 1-21 of each of 2 study periods
|
Total puff volume was created by summing all of the puffs from the cigarette smoked in the lab at each time point (each lab visit).
This value represents the total volume of smoke extracted from a single cigarette and it a standard measure of smoking behavior.
A total puff volume represents the total smoking volume from a cigarette.
Values are reported in milliliters.
Value of interest is the average puff volume across all sessions for all participants in a group and is reported as a key measure of smoking behavior.
Analyses were repeated measures analysis of variance where individual, time and drug were within factors.
|
Days 1-21 of each of 2 study periods
|
|
The Number of Choices of a Nicotine Containing Cigarette Compared to a Non-nicotine Cigarette.
Délai: Days 1, 7, 21 of each of two 21 day study periods
|
Participants were given 4 puff choices (between a nicotine containing and de-nicotinized cigarette) on 6 study visits, for a total of 24 choices.
Number of puffs reported is average across both study periods.
|
Days 1, 7, 21 of each of two 21 day study periods
|
|
Daily Cigarette Consumption
Délai: Two 21 day study periods
|
Average of the number of cigarettes smoked per day
|
Two 21 day study periods
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total Nicotine Metabolites From Urine Samples
Délai: Samples from Day 1 and Day 21 of two 21 day Periods
|
Total urinary metabolites from urine samples collected at Day 1 and Day 21
|
Samples from Day 1 and Day 21 of two 21 day Periods
|
|
Nicotine Levels From Urine Samples
Délai: Samples from Day 1 and Day 21 of two 21 day Periods
|
Nicotine levels from urine samples collected at Day 1 and Day 21.
|
Samples from Day 1 and Day 21 of two 21 day Periods
|
|
Cotinine Levels From Urine Samples
Délai: Samples from Day 1 and Day 21 of two 21 day Periods
|
Cotinine levels from urine samples collected at Day 1 and Day 21.
|
Samples from Day 1 and Day 21 of two 21 day Periods
|
|
Carbon Monoxide Levels
Délai: Samples from Day 1 and Day 21 of two 21 day Periods
|
Exhaled breath carbon monoxide levels collected at Day 1 and Day 21 sessions.
Alveolar carbon monoxide is a validated assessment of smoke exposure.
|
Samples from Day 1 and Day 21 of two 21 day Periods
|
|
Subjective Measures to Assess Smoking Urges
Délai: Days 21 of each of the two 21-day study periods, range 1(low)-7(high)
|
Craving for cigarettes was assessed with the 32-item Questionnaire of Smoking Urges (QSU) during each study visit.
In order to calculate the QSU measure, each item is rated on a Likert-type scale from 1 (strongly disagree) to 7 (strongly agree).
The values are then summed to create a single total score.
Well validated 2 factor subscale scores were also created by summing the item scores for the 2 factors: Factor 1 reflects the desire to smoke for pleasure and Factor 2 reflects urges to smoke to relieve withdrawal-related negative affect.
Internal consistency for each scale across all time points was high (Cronbach's α > 0.95, 0.85, and 0.95 for Factor 1, Factor 2, and QSU total, respectively).
Scale range is 1-7 where 1 is low urge to smoke and 7 represents high urge to smoke.
Data was collected at each time point but outcome measure of interest is end of period.
|
Days 21 of each of the two 21-day study periods, range 1(low)-7(high)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Les troubles mentaux
- Troubles induits chimiquement
- Troubles liés à une substance
- Trouble lié à l'usage du tabac
- Effets physiologiques des médicaments
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Agents cholinergiques
- Agonistes nicotiniques
- Agonistes cholinergiques
- Varénicline
Autres numéros d'identification d'étude
- 808930
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .